- Company News
- Corporate Finance
- Equity Research
- In Media
- M&A Know-how
- Macro and markets
- Market Snapshots
Read the full report here:
DanCann presented investments above our expectations during the first quarter of 2021. This also means that the company is better prepared to serve the market. As important, several events occurred after the end of the first quarter. BIOTECH PHARM1 began operations, a distribution agreement was signed with Tetra Pharma and the pilot programme was extended. The positive news flow has reduced uncertainty. We raise our view on fair value per share to DKK 7.0 (6.5) for the upcoming 6-12 months.
DanCann is still in a pre-commercial phase and had no revenues booked in the first quarter of 2021. Costs were slightly higher than expected as the EBITDA-result amounted to DKK -2.5m. The EBIT-result was DKK -2,6m. Cash flow of DKK -8.6m was lower than expected mainly due to higher investments in BIOTECH PHARM1 and in intangible assets. However, much of the full year’s need for investments should have been taken.
Progressing towards commercialization
On the other side, news flow has been good. DanCann opened its production facility BIOTECH PHARM1 in April 2021. Test production has been initiated, which should lead to a GMP certification at the end of this year after which the bulk-products can be sold on an international market. The facility will focus on rare cannabinoids, which should command a higher price than plants with high content of only THC or CBD. Another important event was the conversion of the LOI with Tetra Pharma into an distribution agreement. This agreement has great potential as it gives DanCann the exclusive rights of distribution of Reduvo Adversa® and Qixleef™ on the Nordic market as well as on the large and relatively well-established German market.
In addition, an important decision was taken by the Danish government: to extend the pilot programme by four years and to allow cannabis production permanently. The regulatory risk for DanCann has consequently been drastically reduced, as it will be possible to maintain production in Denmark for the future no matter what the conclusion of the pilot programme will be.
Given the relatively high level of uncertainty, our assumed sales curves (and associated variable costs) from the various business models have been risk adjusted with probabilities. As the distribution agreement with Tetra Pharma is now in place, previous uncertainty related to this has been eliminated. Thus, we have increased the probabilities for the assumed sales curve from the collaboration to 32 percent from previously 26 percent. Given DMA’s decision, we have also marginally reduced the discount rate. However, we have also increased future investments. All in all, we raise the risk adjusted fair value to DKK 7.0 (6.5) for the upcoming 6-12 months, using a multiple valuation combined with a DCF-model.
Carlsquare AB, www.carlsquare.se, hereinafter referred to as Carlsquare, conducts business with regard to Corporate Finance and Equity Research in which areas it, among other things, publishes information about companies including analyses. The information has been compiled from sources that Carlsquare considers to be reliable. However, Carlsquare cannot guarantee the accuracy of the information. Nothing written in the analysis should be regarded as a recommendation or invitation to invest in any financial instrument, option or the like. Opinions and conclusions expressed in the analysis are intended only for the recipient.
The content may not be copied, reproduced or distributed to another person without the written approval of Carlsquare. Carlsquare shall not be held responsible for any direct or indirect damage caused by decisions made on the basis of information contained in this analysis. Investments in financial instruments provide opportunities for value increases and profits. All such investments are also subject to risks. Risks vary between different types of financial instruments and combinations of these. Historical returns should not be considered as an indication of future returns.
The analysis is not directed to U.S. persons (as defined in Regulation S of the United States Securities Act and interpreted in the United States Investment Company Act 1940) nor may it be disseminated to such persons. The analysis is also not directed to such natural and legal persons where the distribution of the analysis to such persons would result in or entail a risk of a violation of Swedish or foreign law or constitution.
The analysis is a so-called Commissioned Research Report where the analysed Company has signed an agreement with Carlsquare for analysis coverage. The analyses are published on an ongoing basis during the contract period and for a usual fixed remuneration.
Carlsquare may or may not have a financial interest in the subject of this analysis. Carlsquare values the assurance of objectivity and independence and has established procedures for managing conflicts of interest for this purpose.
The analysts Jonatan Andersson, Markus Augustsson, Richard Ramanius and Ulf Boberg do not own and are not allowed to own shares in the company analysed.